Dr Aakash Pandit discusses a comprehensive meta analysis of 17 randomised trials evaluating immune checkpoint inhibitors across all stages of ovarian cancer. Covering more than 11,000 patients, the study provides a broad evidence base to clarify where these therapies offer the greatest clinical value and how they should be incorporated into treatment guidelines.

The findings highlight that the benefit of immune checkpoint inhibitors is highly dependent on disease setting. In frontline treatment, modest improvements in progression free survival were observed, particularly in PD L1 positive patients, but without a clear overall survival advantage.

In contrast, more consistent benefits were seen in recurrent disease, where both progression free and overall survival improved, especially in platinum sensitive settings. In platinum resistant disease, survival gains were also observed, with combination strategies enhancing efficacy.

Dr Pandit says that safety profiles varied by setting, with higher rates of significant toxicity seen in frontline and combination approaches, while monotherapy in resistant disease appeared comparatively better tolerated.

Overall, the discussion emphasizes the need for a more tailored approach to immunotherapy in ovarian cancer.

Experts outline how these data support prioritising checkpoint inhibitors in recurrent disease while adopting biomarker driven strategies and careful toxicity management in earlier lines, helping to refine future international clinical guidelines.